Is Snus Bad for You? Risks Compared to Cigarettes

Snus is not harmless, but the evidence consistently shows it carries substantially lower health risks than cigarettes. A large pooled analysis of eight prospective studies found that exclusive snus users had about a 28% higher risk of dying from any cause compared to people who never used tobacco, while the corresponding figure for smoking is several times that. The gap between “not safe” and “far safer than smoking” is where most of the confusion lives, and the details matter depending on what you’re worried about: cancer, heart disease, gum damage, diabetes, or addiction.

How Snus Differs From Cigarettes Chemically

The single biggest difference is combustion. Cigarettes burn tobacco at high temperatures, producing thousands of chemicals including tar, carbon monoxide, and heavy concentrations of carcinogens. Snus is a moist, pasteurized tobacco product placed under the upper lip. Because nothing is burned, users avoid inhaling the cocktail of toxic gases and particulates that drive lung cancer, chronic obstructive pulmonary disease, and much of the cardiovascular damage from smoking.

That said, snus still contains tobacco-specific nitrosamines (TSNAs), the most worrying carcinogens in smokeless tobacco. The levels vary a lot depending on where the product is made. American snus products contain roughly twice the concentration of the key nitrosamines NNN and NNK compared to Northern European snus, with total TSNA levels averaging about 2,086 ng/g in U.S. products versus 1,100 ng/g in Northern European ones.¹ Swedish manufacturers follow a voluntary quality standard called GOTHIATEK that caps nitrosamine and heavy metal levels, so the Swedish product most commonly studied in the research tends to be cleaner than what’s sold elsewhere.

Cancer Risks Are Lower, but Not Zero

The cancer picture is where snus separates most dramatically from cigarettes. Smoking is a well-established cause of cancers in the lung, throat, mouth, bladder, stomach, pancreas, and more. Snus users, by contrast, show no increased risk for lung cancer (there’s no smoke to inhale) and appear to face little to no elevated risk of oral cancer. A systematic review found that five out of six epidemiological studies reported no elevated oral cancer risk among snus users, though a few case reports have described tumors at the exact site where the pouch sits.² A large cohort study of male construction workers in Sweden similarly found no association between snus and oral or lung cancer.³

The picture is murkier for cancers of the digestive tract. That same construction-worker study reported a doubled risk of pancreatic cancer among snus users who had never smoked. But a later pooled analysis of nine prospective studies found no association between current snus use and pancreatic cancer after adjusting for smoking history.⁴ The contradiction has never been fully resolved, though the larger pooled data carries more statistical weight. A systematic review of cancer risk among exclusive snus users flagged possible increased risks for cancers of the esophagus, stomach, pancreas, and rectum, and also noted that snus users who were diagnosed with cancer appeared to have worse survival outcomes.⁵ So while snus clearly does not carry the broad cancer burden of cigarettes, the evidence for certain gastrointestinal cancers is still unsettled.

Cardiovascular Effects

Smoking roughly doubles your risk of heart attack and stroke, primarily because the combustion products damage blood vessel walls, accelerate plaque buildup, and reduce oxygen delivery. Snus removes most of that chemical assault, and several large studies have found no increased risk of heart attack, heart failure, or atrial fibrillation in snus users after accounting for smoking history. A prospective Swedish cohort study did find one notable exception: among people who had never smoked, snus use was linked to about a 50% higher risk of stroke.⁶

There are also signs of subtler vascular damage. Research on healthy male snus users has found increased arterial stiffness, a measure of how rigid your blood vessel walls have become, compared to non-users. In one study, snus users had significantly higher pulse wave velocity and augmentation index than controls, despite having similar blood pressure and heart rate readings.⁷ A separate study confirmed the arterial stiffness finding and described it as a blood-pressure-independent risk factor for cardiovascular disease.⁸ In practical terms, this means snus might nudge your cardiovascular risk up modestly over a lifetime, but nowhere near what smoking does. For someone switching from cigarettes, it’s a vast improvement. For someone who never used tobacco at all, it’s an unnecessary addition of risk.

Type 2 Diabetes Risk

One finding that surprises many people is that snus appears to increase the risk of type 2 diabetes in a dose-dependent way. A pooled analysis of five Swedish cohorts found that current snus users had about a 15% higher risk of developing type 2 diabetes. Among heavy users consuming five to six boxes per week, the risk rose to roughly 42% above non-users, and for those using seven or more boxes weekly the risk was about 68% higher.⁹ The mechanism likely involves nicotine’s effects on insulin sensitivity and glucose metabolism. Swedish and Norwegian data also link both smoking and snus use to latent autoimmune diabetes in adults (LADA), an autoimmune form of diabetes that develops more slowly than type 1.¹⁰ This is an area where snus and cigarettes may both be contributing to the same problem through their shared ingredient: nicotine.

Overall Mortality

The most comprehensive look at whether snus shortens your life comes from a pooled analysis of eight prospective Swedish studies. Exclusive current snus users had a 28% higher risk of death from any cause compared to people who had never used tobacco. Cardiovascular mortality was about 27% higher, cancer mortality about 12% higher, and death from other causes about 37% higher.¹¹ The risks increased with duration of use but not with the weekly amount consumed, suggesting that how long you’ve been using matters more than how many pouches you go through in a given week.

To put these numbers in context, cigarette smoking roughly doubles or triples all-cause mortality in most long-term studies. A 28% increase is meaningfully above zero but in a different league entirely from smoking. That’s the core tension in the snus debate: it is a genuine health risk, and it is dramatically less dangerous than cigarettes. Both of those things are true simultaneously.

What Snus Does to Your Mouth

The most visible and consistent effect of snus use is on the oral tissues where you place it. Whitish, leathery patches called smokeless tobacco keratosis develop at the placement site in a large proportion of regular users. The good news is that these mucosal changes tend to reverse partially or completely after you stop using snus.¹² Gum recession at the placement site is another well-documented effect, particularly among users of loose snus (as opposed to portioned pouches). The combination of mechanical pressure from the pouch and the chemical effects of the tobacco appears to push the gum tissue away from the tooth, exposing more of the root.¹³ The recession is generally localized to the spot where the snus sits. Deeper periodontal destruction, like bone loss around teeth, has not been consistently linked to snus after accounting for oral hygiene habits and whether someone also smokes.

If you use snus, the practical takeaway is to rotate placement sites and be aware that your gums at the habitual spot will probably recede over time. That recession doesn’t reverse the way the white patches do.

Nicotine Delivery and Addiction

Snus delivers nicotine through the lining of the mouth rather than through the lungs, and this changes the experience in ways that matter for both satisfaction and dependence. Nicotine from a cigarette hits peak blood levels in about five to eight minutes because it crosses into the bloodstream almost instantly through the lung tissue. Snus takes much longer, roughly 20 to 65 minutes to reach its peak concentration.¹⁴ That slower delivery means a less intense rush but a longer, more sustained nicotine presence.

How much nicotine actually gets into your blood depends on the strength of the product. A standard 4 mg nicotine pouch delivers peak blood levels that are roughly 70% of what a cigarette delivers. But higher-strength products can exceed cigarette-level nicotine delivery. In one study, a 30 mg nicotine pouch produced nearly double the peak blood concentration of a cigarette.¹⁵ Products at 10 mg and above have been shown to match or exceed cigarette nicotine levels in terms of both peak concentration and total exposure over several hours.¹⁶

Unsurprisingly, snus is about as addictive as cigarettes. Research comparing dependence levels found no significant difference in scores on the Heaviness of Smoking Index between smokers and snus users. About a third of snus users said it would be very hard to give up, nearly identical to the proportion of smokers who said the same.¹⁷ If you’re thinking about snus as a consequence-free alternative to cigarettes, the addiction itself is a real cost even if the physical health effects are less severe.

Snus During Pregnancy

Pregnant women sometimes assume that because snus avoids smoke, it’s a safe alternative during pregnancy. It isn’t. A systematic review of pregnancy outcomes found that snus use during pregnancy was associated with increased risks across several categories: about a 43% higher risk of stillbirth, a 69% higher risk of extremely premature birth, a 26% higher risk of the baby being born small for gestational age, and a possible link to oral cleft malformations.¹⁸ The review noted low confidence in the precision of these estimates, but the direction was consistent: nicotine exposure during pregnancy, regardless of its source, carries real risks to fetal development.

Sweden’s Population-Level Experiment

Sweden offers the closest thing to a natural experiment on what happens when a country replaces smoking with snus on a large scale. Swedish men have among the lowest smoking rates in Europe, and a long tradition of snus use. The result is striking: Swedish men have Europe’s lowest level of mortality attributable to smoking. One modeling study estimated that roughly 3,000 lives per year have been saved in Sweden because of the population-level shift from cigarettes to snus.¹⁹

This is the foundation of the “harm reduction” argument: if people who would otherwise smoke can be moved to snus instead, the public health payoff is enormous even though snus itself isn’t risk-free. The argument is controversial because critics worry it normalizes tobacco use, potentially attracting people who would never have smoked in the first place. In Scandinavia, survey data suggests snus was the most commonly used cessation aid among Norwegian adults who quit smoking, and its use was associated with a higher likelihood of successfully quitting.²⁰ A U.S. randomized trial comparing snus to nicotine lozenges for smoking cessation found quit rates were similarly low and not significantly different across groups, suggesting snus is not especially effective as a structured cessation tool in clinical settings.²¹ The disconnect may reflect that in Scandinavia, snus is a culturally embedded product people switch to voluntarily, whereas in a clinical trial setting it’s presented as just another tool.

What About Using Both

A common worry is that people who start using snus won’t actually quit smoking and will end up as dual users, doubling down on risk. The evidence here is somewhat reassuring. A systematic review of dual use found that out of 51 interaction risk ratios examined, only one showed a statistically significant increase above what you’d expect. Dual users actually tend to smoke fewer cigarettes than people who only smoke, which may partly offset the added risk of the snus.²² This doesn’t mean dual use is harmless. It means that adding snus on top of reduced smoking doesn’t appear to create a worse-than-smoking scenario.

Tobacco-Free Nicotine Pouches

Products like ZYN and similar brands are sometimes confused with snus, but they contain no tobacco leaf at all. Instead, they deliver pharmaceutical-grade nicotine through a plant fiber or cellulose pouch. The toxicant profile is dramatically cleaner. In one analysis, 38 of 43 tested harmful compounds in ZYN pouches fell below the level of detection, including all tested nitrosamines and polycyclic aromatic hydrocarbons. The handful of quantifiable compounds in ZYN were present at levels 69–93% lower than in snus, depending on the substance.²³ A separate comparative analysis confirmed that oral nicotine pouches contained lower levels of analytes than snus across the board, with reductions exceeding 90% for most tested compounds.²⁴

The long-term health effects of tobacco-free pouches haven’t been studied for decades the way snus and cigarettes have, so it’s too early to say with certainty how they compare on hard outcomes like cancer or heart disease. What can be said is that they eliminate the tobacco-specific toxicants that are the most plausible drivers of snus-related disease. They do not, however, eliminate the nicotine, which means the addiction potential, the diabetes risk pathway, and the cardiovascular effects of nicotine itself all remain in play. A cross-sectional study of nicotine pouch users in Saudi Arabia found that about 81% reported gastrointestinal symptoms like bloating, nausea, or heartburn, and roughly 39% reported some degree of psychological impact from their use.²⁵ Self-reported surveys like this have obvious limitations, but they suggest nicotine itself isn’t exactly easy on the body even without tobacco.

Snus and Mental Health

One area where snus appears clearly better than smoking is mental health. A large Norwegian population study found no significant association between current snus use and anxiety or depression after adjusting for background variables. Smoking, by contrast, was significantly associated with both. Among men, the adjusted effect of smoking on anxiety was larger than any effect seen for snus. Among women, the association between smoking and depression was particularly strong.²⁶ One intriguing wrinkle: men who had previously used snus but stopped did show a small but significant association with anxiety. Whether this reflects withdrawal effects, personality traits that lead both to snus cessation and anxiety, or something else entirely isn’t clear from the data. But the overall finding is consistent with the pattern across other outcomes: snus comes out somewhere between no-tobacco and cigarettes, usually much closer to the no-tobacco end.

The American and European Product Gap

If you’re reading this from the United States, it’s worth knowing that not all snus is the same product. The large body of reassuring epidemiological data on snus comes overwhelmingly from Scandinavia, where the product is manufactured under tighter quality controls and contains lower levels of carcinogens. American snus products carry roughly double the concentration of key nitrosamines. This doesn’t automatically mean American snus is twice as dangerous (the dose-response relationship for these compounds isn’t perfectly linear), but it does mean you can’t directly apply Swedish safety data to American products and assume the same risk level applies. The European Union currently bans the sale of snus everywhere except Sweden, where it has a historical exemption. That regulatory split means the product is well-studied in one population but relatively unfamiliar in most of the rest of the world, which makes evidence-based personal decisions harder for anyone outside Scandinavia.